F
Fabio A.B. Schutz
Researcher at Harvard University
Publications - 86
Citations - 9410
Fabio A.B. Schutz is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 29, co-authored 81 publications receiving 7604 citations. Previous affiliations of Fabio A.B. Schutz include Niigata University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors.
Jonathan E. Rosenberg,Lillian Werner,Aristotelis Bamias,Toni K. Choueiri,Fabio A.B. Schutz,Rachel S. Park,Robert O'Brien,Elizabeth A. Guancial,Robert W. Ross,David M. Berman,Markus Riester,Rosina T. Lis,Massimo Loda,Edward C. Stack,Franziska Michor,Nabil Chehab,Joaquim Bellmunt Molins +16 more
TL;DR: This data indicates that FGFR3 protein expression may represent a valid therapeutic target in metastatic UC and the prevalence of both mutation and overexpression is unknown.
Journal ArticleDOI
Consensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries.
Fernando Sabino Marques Monteiro,Fabio A.B. Schutz,Igor Alexandre Protzner Morbeck,Diogo Assed Bastos,Fernando Vidigal de Pádua,L. Costa,Manuel C. Maia,José Augusto Rinck,Stenio de Cassio Zequi,Karine Martins da Trindade,Wladimir Alfer,William C. Nahas,Lucas V. dos Santos,Robson Ferrigno,Diogo Augusto Rodrigues da Rosa,Juan Pablo Sade,Francisco Javier Orlandi,Fernando Nunes Galvão de Oliveira,Andrey Soares +18 more
TL;DR: In this article, the authors presented a summary of the treatment and follow-up recommendations for the biochemical recurrence in castration-sensitive prostate cancer acquired through a questionnaire administered by the patient.
Journal ArticleDOI
Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study.
Fabio A.B. Schutz,Kathryn P. Gray,Mark Pomerantz,Michael B. Atkins,Jonathan E. Rosenberg,Michelle S. Hirsch,David F. McDermott,Gwo-Shu Mary Lee,Sabina Signoretti,Philip W. Kantoff,Matthew L. Freedman,Toni K. Choueiri +11 more
TL;DR: This is the first study to implicate germline variations in critical signaling pathways with cancer recurrence in patients with localized RCC, and three SNPs in 2 genes were found to be highly predictive of RFI in univariate analysis.
Journal ArticleDOI
Double Immune Checkpoint Blockade in Renal Cell Carcinoma
TL;DR: The principles of immunotherapy and its role in RCC are summarized, an update on double checkpoint blockade is provided, and the major challenges withdouble checkpoint blockade are discussed.
Journal ArticleDOI
Role of second-line gemcitabine after FOLFIRINOX failure in advanced pancreatic adenocarcinoma: A retrospective analysis.
Aline Da Rocha Lino,Rodnei Merlrina Martins Junior,Carina Mina Abrahao,Raphael Brandao Moreira,Tarcia Tarciane Soares de Sousa,Jessica Ribeiro Gomes,Matheus Bongers Alessandretti,Marcus Paulo Fernandes Amarante,Andrea Malta Ferrian,Fabio A.B. Schutz,Carolina Kawamura,Rafael Schmerling,Marcelo Rocha Cruz,Renata D'Alpino Peixoto,Marcel Cerqueira Cesar Machado,Antonio C. Buzaid,Fernando C. Maluf +16 more
TL;DR: The experience with single-agent gemcitabine as a second-line treatment for advanced pancreatic cancer patients who progressed on FOLFIRINOX is reported, with good results for patients with metastatic disease.